Investigational New Drugs

, Volume 23, Issue 3, pp 205–211 | Cite as

Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines

  • Frank Mayer
  • Sandra Mueller
  • Elke Malenke
  • M. Kuczyk
  • Jörg T. Hartmann
  • Carsten BokemeyerEmail author


Background: Germ cell tumours (GCTs) are highly sensitive to cisplatin-based chemotherapy. The inability to arrest the cell cycle at the G1/S-check-point due to a lack of retinoblastoma gene product RB has been suggested as one potential explanation for this feature. Flavopiridol (FP), an inhibitor of cyclin dependent kinases, causes cell cycle arrest or apoptosis depending on the relation of the transcription factor E2F1 and RB.

Methods: The effect of FP was evaluated in GCT-derived cell lines NT2, 2102 EP and NCCIT in comparison to cell lines derived from ovarian cancer (SKOV), breast cancer (MCF7), and cervical cancer (HeLa) using the MTT-assay. Cell cycle progression and induction of apoptosis were assessed by flow cytometry and immunoblot analysis of PARP-cleavage.

Results: FP did not affect cell cycle progression and proliferation of GCT cell lines at sublethal doses. At higher concentrations, cell death occurred independent of cell cycle progression. The IC50 was approximately fivefold lower for the three GCT cell lines (60/60/70 nM) than for the other tumour cell lines tested (350/280/300 nM). Lethal doses in vitro were markedly lower than plasma concentrations of FP achieved in clinical studies. In vitro sensitivity to FP did not correlate with that to cisplatin. The cell lines NTera2 and NCCIT showed comparable responses to FP despite differing in their IC50 to cisplatin by factor 4. Flow cytometry and immunoblot for PARP indicated apoptotic cell death induced by FP. Synergism between either cisplatin or paclitaxel and FP was not observed. However, at low concentrations, cytotoxicity of FP and cisplatin appeared to be additive.

Conclusion: These prelinical investigations suggest a significant antitumour activity of FP in GCT. GCT derived cell lines were far more responsive to FP than cell lines derived from other solid tumours. In contrast to other models, FP did not induce cell cycle arrest in the GCT-derived cell lines tested, possibly due to the known lack of RB-expression in GCTs. However, apoptosis was induced unrelated to cell cycle progression already at low concentrations. No cross resistance between FP and cisplatin was observed. A clinical trial evaluating the activity of FP in patients with cisplatin-refractory GCTs appears to be warranted.


Cervical Cancer Paclitaxel Cell Cycle Arrest Cell Cycle Progression Retinoblastoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Einhorn LH: Treatment of testicular cancer: A new and improved model. J Clin Oncol 8: 1777–1781, 1990PubMedGoogle Scholar
  2. 2.
    Kollmannsberger C, Mayer F, Kuczyk M, Kanz L, Bokemeyer C: Treatment of patients with metastatic germ cell tumors relapsing after high-dose chemotherapy. World J Urol 19: 120–125, 2001CrossRefPubMedGoogle Scholar
  3. 3.
    Kollmannsberger C, Mayer F, Pressler H, Koch S, Kanz L, Oosterhuis JW, Looijenga LH, Bokemeyer C: Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer. Cancer 95: 301–308, 2002CrossRefPubMedGoogle Scholar
  4. 4.
    Madani A, Kemmer K, Sweeney C, Corless C, Ulbright T, Heinrich M, Einhorn L: Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors. Ann Oncol 14: 873–880, 2003CrossRefPubMedGoogle Scholar
  5. 5.
    Mayer F, Honecker F, Looijenga LH, Bokemeyer C: Towards an understanding of the biological casis of response to cisplatin-based chemotherapy in germ-cell tumors. Ann Oncol 14: 825–832, 2003CrossRefPubMedGoogle Scholar
  6. 6.
    Kersemaekers AM, Mayer F, Molier M, van Weeren PC, Oosterhuis JW, Bokemeyer C, Looijenga LH: Role of P53 and MDM2 in treatment response of human germ cell tumors. J Clin Oncol 20: 1551–1561, 2002CrossRefPubMedGoogle Scholar
  7. 7.
    Mayer F, Stoop H, Scheffer GL, Scheper R, Oosterhuis JW, Looijenga LH, Bokemeyer C: Molecular determinants of treatment response in human germ cell tumors. Clin Cancer Res 9: 767–773, 2003PubMedGoogle Scholar
  8. 8.
    Strohmeyer T, Reissmann P, Cordon-Cardo C, Hartmann M, Ackermann R, Slamon D: Correlation between retinoblastoma gene expression and differentiation in human testicular tumors. Proc Natl Acad Sci USA 88: 6662–6666, 1991PubMedGoogle Scholar
  9. 9.
    Senderowicz AM, Sausville EA: Preclinical and clinical development of cyclin-dependent kinase modulators. J Natl Cancer Inst 92: 376–387, 2000CrossRefPubMedGoogle Scholar
  10. 10.
    Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, Hill K, Steinberg SM, Figg WD, Tompkins A, Arbuck SG, Sausville EA: Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 16: 2986–2999, 1998PubMedGoogle Scholar
  11. 11.
    Jiang J, Matranga CB, Cai D, Latham VM, Jr., Zhang X, Lowell AM, Martelli F, Shapiro GI: Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity. Cancer Res 63: 7410–7422, 2003PubMedGoogle Scholar
  12. 12.
    Motwani M, Rizzo C, Sirotnak F, She Y, Schwartz GK: Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol Cancer Ther 2: 549–555, 2003PubMedGoogle Scholar
  13. 13.
    Jung C, Motwani M, Kortmansky J, Sirotnak FM, She Y, Gonen M, Haimovitz-Friedman A, Schwartz GK: The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates gamma-Irradiation-Induced Apoptosis in Colon and Gastric Cancer Cells. Clin Cancer Res 9: 6052–6061, 2003PubMedGoogle Scholar
  14. 14.
    Jung CP, Motwani MV, Schwartz GK: Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 7: 2527–2536, 2001PubMedGoogle Scholar
  15. 15.
    Aklilu M, Kindler HL, Donehower RC, Mani S, Vokes EE: Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol 14: 1270–1273, 2003CrossRefPubMedGoogle Scholar
  16. 16.
    Schwartz GK, Ilson D, Saltz L, O’Reilly E, Tong W, Maslak P, Werner J, Perkins P, Stoltz M, Kelsen D: Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 19: 1985–1992, 2001PubMedGoogle Scholar
  17. 17.
    Shapiro GI, Supko JG, Patterson A, Lynch C, Lucca J, Zacarola PF, Muzikansky A, Wright JJ, Lynch TJ, Jr., Rollins BJ: A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. Clin Cancer Res 7: 1590–1599, 2001PubMedGoogle Scholar
  18. 18.
    Stadler WM, Vogelzang NJ, Amato R, Sosman J, Taber D, Liebowitz D, Vokes EE: Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: A University of Chicago Phase II Consortium study. J Clin Oncol 18: 371–375, 2000PubMedGoogle Scholar
  19. 19.
    Wang N, Perkins KL, Bronson DL, Fraley EE: Cytogenetic evidence for premeiotic transformation of human testicular cancers. Cancer Res 41: 2135–2140, 1981PubMedGoogle Scholar
  20. 20.
    Sieuwerts AM, Klijn JG, Peters HA, Foekens JA: The MTT tetrazolium salt assay scrutinized: how to use this assay reliably to measure metabolic activity of cell cultures in vitro for the assessment of growth characteristics, IC50-values and cell survival. Eur J Clin Chem Clin Biochem 33: 813–823, 1995PubMedGoogle Scholar
  21. 21.
    Koch S, Mayer F, Honecker F, Schittenhelm M, Bokemeyer C: Efficacy of cytotoxic agents used in the treatment of testicular germ cell tumours under normoxic and hypoxic conditions in vitro. Br J Cancer 89: 2133–2139, 2003CrossRefPubMedGoogle Scholar
  22. 22.
    Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C: A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271–279, 1991CrossRefPubMedGoogle Scholar
  23. 23.
    Chaganti RS, Houldsworth J: Genetics and biology of adult human male germ cell tumors. Cancer Res 60: 1475–1482, 2000PubMedGoogle Scholar
  24. 24.
    Zhai S, Senderowicz AM, Sausville EA, Figg WD: Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development. Ann Pharmacother 36: 905–911, 2002CrossRefPubMedGoogle Scholar
  25. 25.
    Sedlacek HH: Mechanisms of action of flavopiridol. Crit Rev Oncol Hematol 38: 139–170, 2001PubMedGoogle Scholar
  26. 26.
    Mayer F, Gillis AJ, Dinjens W, Oosterhuis JW, Bokemeyer C, Looijenga LH. Microsatellite instability of germ cell tumors is associated with resistance to systemic treatment. Cancer Res 62: 2758–2760, 2002PubMedGoogle Scholar
  27. 27.
    Burger H, Nooter K, Boersma AW, Kortland CJ, Stoter G. Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in testicular germ cell tumour cell lines. Int J Cancer 73: 592–599, 1997CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Frank Mayer
    • 1
  • Sandra Mueller
    • 1
  • Elke Malenke
    • 1
  • M. Kuczyk
    • 2
  • Jörg T. Hartmann
    • 1
  • Carsten Bokemeyer
    • 1
    • 3
    Email author
  1. 1.Department of Oncology, Hematology, Immunology, and RheumatologyUniversity of Tübingen Medical Center
  2. 2.Department of UrologyUniversity of TübingenTübingenGermany
  3. 3.Department of Oncology, Hematology, Immunology, and RheumatologyUniversity of Tuebingen Medical CenterTuebingenGermany

Personalised recommendations